Table 2.

Completed clinical trials on CAR-T cell therapy in pancreatic cancer.

Trial Number	Phase	Target	Number of Patients/Treatment	Efficacy	Reference
NCT02159716	I	MSLN	6 PDAC patients with or without cyclophosphamide preconditioning/single CAR-T cell infusion	3/5 evaluable patients with PD; 2/5 patients with SD	Haas et al. [83]
NCT01897415	I	MSLN	6 PDAC patients (information about preconditioning not available)/3 CAR-T cells infusion cycles 3 times/week for 3 weeks	2/3 evaluable patients with SD; 1/3 patients with DP	Beatty et al. [84]
NCT01869166	I	EGFR	16 PDAC patients with nab-paclitaxel and cyclophosphamide preconditioning/single CAR-T cells infusion	4/14 evaluable patients with PR; 8/14 patients with SD; 2/14 patients with DP	Liu et al. [85]
NCT01935843	I	HER2	11 PDAC patients with nab-paclitaxel and cyclophosphamide preconditioning/1–2 CAR-T cells infusion cycles for 3–5 days	2/11 evaluable patients with SD	Feng et al. [86]
NCT04404595	Ib	CLDN18.2	6 PDAC patients with fludarbine, nab-paclitaxel, and cyclophosphamide preconditioning/single CAR-T cells infusion	2/5 evaluable patients with SD	Botta et al. [87]
NCT03874897	I	CLDN18.2	5 PDAC patients: 3 with fludarbine, nab-paclitaxel, and cyclophosphamide preconditioning, 2 with fludarbine, gemcitabine, and cyclophosphamide preconditioning/single CAR-T cells infusion	1/5 evaluable patients with PD; 3/5 patients with SD	Oi et al. [88]
NCT02541370	I	CD133	23 PDAC patients with nab-paclitaxel and cyclophosphamide preconditioning/2–4 CAR-T cells infusion cycles	2/7 evaluable patients with PD; 3/7 patients with SD; 2/7 patients with PR	Wang et al. [89]

CAR, chimeric antigen receptor; CLDN18.2, claudin18.2; DP, disease progression; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; MSLN, mesothelin; PD, progressive disease; PDAC, pancreatic ductal adenocarcinoma; PR, partial response; SD, stable disease.